IL112033A0 - Methods of inhibiting pulmonary hypertensive diseases - Google Patents
Methods of inhibiting pulmonary hypertensive diseasesInfo
- Publication number
- IL112033A0 IL112033A0 IL11203394A IL11203394A IL112033A0 IL 112033 A0 IL112033 A0 IL 112033A0 IL 11203394 A IL11203394 A IL 11203394A IL 11203394 A IL11203394 A IL 11203394A IL 112033 A0 IL112033 A0 IL 112033A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- hypertensive diseases
- pulmonary hypertensive
- inhibiting pulmonary
- inhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/171,386 US5447941A (en) | 1993-12-21 | 1993-12-21 | Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL112033A0 true IL112033A0 (en) | 1995-03-15 |
Family
ID=22623551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11203394A IL112033A0 (en) | 1993-12-21 | 1994-12-19 | Methods of inhibiting pulmonary hypertensive diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5447941A (no) |
| EP (1) | EP0659426A1 (no) |
| JP (1) | JPH07215856A (no) |
| KR (1) | KR950016725A (no) |
| CN (1) | CN1109753A (no) |
| AU (1) | AU8154994A (no) |
| CA (1) | CA2138496A1 (no) |
| CZ (1) | CZ320894A3 (no) |
| HU (1) | HUT71222A (no) |
| IL (1) | IL112033A0 (no) |
| NO (1) | NO944927L (no) |
| RU (1) | RU94045149A (no) |
| ZA (1) | ZA9410100B (no) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
| US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5595722A (en) | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
| CA2162586C (en) | 1993-05-13 | 2006-01-03 | David J. Grainger | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
| US6562862B1 (en) * | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| US5840747A (en) * | 1995-06-07 | 1998-11-24 | Eli Lilly And Company | Calcium channel antagonists |
| AU6277396A (en) | 1995-06-07 | 1996-12-30 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
| IL120266A (en) * | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
| US5811437A (en) * | 1996-05-21 | 1998-09-22 | Eli Lilly And Company | Methods of increasing nitric oxide synthesis |
| US6693130B2 (en) * | 1999-02-18 | 2004-02-17 | Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of hypertension |
| US6117911A (en) * | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| WO2000045806A1 (en) * | 1999-02-03 | 2000-08-10 | Eli Lilly And Company | α1-ADRENERGIC RECEPTOR ANTAGONISTS |
| HUP0200871A3 (en) | 1999-05-04 | 2004-04-28 | Strakan Int Ltd | Androgen glycosides and androgenic activity thereof |
| JP2004500906A (ja) * | 1999-11-12 | 2004-01-15 | ルーベン， レオ | 電気的調節および化学的調節のための心臓デバイス、ならびに心肺障害の処置のための血管作用性腸ペプチド |
| GB2362101A (en) * | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
| GB2374412A (en) * | 2001-04-11 | 2002-10-16 | Karobio Ab | Hypertension treatment and assay |
| US6854563B2 (en) * | 2001-12-17 | 2005-02-15 | General Electric Company | Wayside rail lubrication apparatus and method |
| TW200740442A (en) * | 2005-08-29 | 2007-11-01 | Taiho Pharmaceutical Co Ltd | Therapeutic agent for hypertension |
| WO2011099942A1 (en) | 2010-02-09 | 2011-08-18 | Silverstone Pharma | New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy |
| GB201705124D0 (en) | 2017-03-30 | 2017-05-17 | Innospec Ltd | Composition, method and use |
| KR102132554B1 (ko) * | 2019-02-25 | 2020-07-09 | 가톨릭대학교 산학협력단 | 랄록시펜을 유효성분으로 함유하는 전신경화증의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3947470A (en) * | 1974-06-20 | 1976-03-30 | Smithkline Corporation | Substituted benzofurans and benzothiophenes |
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
| JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
-
1993
- 1993-12-21 US US08/171,386 patent/US5447941A/en not_active Expired - Fee Related
-
1994
- 1994-12-19 CN CN94119744A patent/CN1109753A/zh active Pending
- 1994-12-19 ZA ZA9410100A patent/ZA9410100B/xx unknown
- 1994-12-19 CA CA002138496A patent/CA2138496A1/en not_active Abandoned
- 1994-12-19 CZ CZ943208A patent/CZ320894A3/cs unknown
- 1994-12-19 EP EP94309484A patent/EP0659426A1/en not_active Withdrawn
- 1994-12-19 NO NO944927A patent/NO944927L/no unknown
- 1994-12-19 KR KR1019940034916A patent/KR950016725A/ko not_active Application Discontinuation
- 1994-12-19 JP JP6314539A patent/JPH07215856A/ja active Pending
- 1994-12-19 IL IL11203394A patent/IL112033A0/xx unknown
- 1994-12-19 HU HU9403657A patent/HUT71222A/hu unknown
- 1994-12-19 RU RU94045149/14A patent/RU94045149A/ru unknown
- 1994-12-19 AU AU81549/94A patent/AU8154994A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0659426A1 (en) | 1995-06-28 |
| HU9403657D0 (en) | 1995-02-28 |
| NO944927L (no) | 1995-06-22 |
| RU94045149A (ru) | 1996-10-20 |
| CA2138496A1 (en) | 1995-06-22 |
| ZA9410100B (en) | 1996-06-19 |
| KR950016725A (ko) | 1995-07-20 |
| CZ320894A3 (en) | 1995-08-16 |
| CN1109753A (zh) | 1995-10-11 |
| AU8154994A (en) | 1995-06-29 |
| JPH07215856A (ja) | 1995-08-15 |
| NO944927D0 (no) | 1994-12-19 |
| HUT71222A (en) | 1995-11-28 |
| US5447941A (en) | 1995-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL112033A0 (en) | Methods of inhibiting pulmonary hypertensive diseases | |
| IL112043A0 (en) | Methods of inhibiting emperfect tissue repair | |
| ZA9410083B (en) | Methods of inhibiting autoimmune diseases | |
| HU9403666D0 (en) | Methods of inhibiting breast disorders | |
| PL313740A1 (en) | Method of | |
| PL331766A1 (en) | Method of inhibiting fas expression | |
| IL118574A0 (en) | Methods of inhibiting melanoma | |
| PL305237A1 (en) | Method of obtaining 3-aminopyridines from 3-nitropyridines | |
| GB9606308D0 (en) | Articles of jewelery | |
| ZA949404B (en) | Methods of inhibiting the effects of amyloidogenic proteins | |
| ZA957949B (en) | Methods of inhibiting endometrial mitroses | |
| ZA944577B (en) | Preparation of aminopropionitriles | |
| GB2275266A8 (en) | Preparation of 2-methyl-3-aminobenzotrifluoride | |
| PL332088A1 (en) | Production of 1-butyl-4-piperidinylmethylamine | |
| PL297500A1 (en) | Method of obtaining 4-phenyl-benzophenone | |
| GB9709084D0 (en) | Methods of inhibiting immune-complex diseases | |
| GB9725593D0 (en) | Method of ornamentation | |
| GB9607447D0 (en) | Item of jewellery | |
| PL310521A1 (en) | Method of obtaining alkylbenzenosulphonic acid | |
| PL332941A1 (en) | Method of obtaining naphtyridinic compounds and novel intermediate compounds | |
| GB9612215D0 (en) | Manufacture of articles | |
| PL299255A1 (en) | Method of obtaining meproscilarine | |
| ZA962427B (en) | Point of sale structure | |
| ZA942247B (en) | Method of construction | |
| GB9322922D0 (en) | Improved methods of sublimation |